Article Information
History
- October 8, 2021.
Article Versions
- Version 1 (August 25, 2021 - 09:49).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Venice Servellita1,2,
- Alicia Sotomayor-Gonzalez1,2,
- Amelia S. Gliwa1,2,
- Erika Torres4,
- Noah Brazer1,2,
- Alicia Zhou4,
- Katherine T. Hernandez5,
- Maddie Sankaran5,
- Baolin Wang1,2,
- Daniel Wong1,2,
- Candace Wang1,2,
- Yueyuan Zhang1,2,
- Kevin R Reyes1,2,
- Dustin Glasner1,2,
- Xianding Deng1,2,
- Jessica Streithorst1,2,
- Steve Miller1,2,
- Edwin Frias6,
- Mary Rodgers6,
- Gavin Cloherty6,
- John Hackett Jr.6,
- Susan Philip5,
- Scott Topper,
- Darpun Sachdev5 and
- Charles Y. Chiu1,2,7,8,*
- 1Department of Laboratory Medicine, University of California San Francisco, California, USA
- 2UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA
- 4Color Genomics, Inc., San Francisco, California, USA
- 5San Francisco Department of Public Health, San Francisco, California, USA
- 6Abbott Laboratories, Abbott Park, Illinois, USA
- 7Department of Medicine, University of California San Francisco, California, USA
- 8Innovative Genomics Institute, University of California Berkeley, Berkeley, California, USA
- ↵*corresponding author; email: charles.chiu{at}ucsf.edu
Posted October 08, 2021.
Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California
